<DOC>
	<DOCNO>NCT00529451</DOCNO>
	<brief_summary>This study design investigate efficacy , safety tolerability aliskiren 300 mg , 150 mg 75 mg compare ramipril 5 mg patient essential hypertension .</brief_summary>
	<brief_title>Safety Efficacy Aliskiren 300 mg , 150 mg 75 mg Patients With Essential Hypertension Compared Ramipril 5 mg</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Patients must msDBP â‰¥ 90 mmHg &lt; 110 mmHg visit immediately prior Visit 3 Patients must msDBP &gt; OR= 95 mmHg &lt; 110 mmHg Visit 3 Patients must absolute difference &lt; =10 mmHg mean sit diastolic blood pressure ( msDBP ) Visit 2 Visit 3 Severe hypertension ( grade 3 WHO classification ; msDBP &gt; or= 110 mmHg and/or msSBP &gt; = 180 mmHg ) . History evidence secondary form hypertension . History transient ischemic cerebral attack within 12 month visit 1 . Current angina pectoris require pharmacological therapy ( patient stable dose oral topical nitrate ) Type 1 Type 2 diabetes mellitus glycosylated hemoglobin ( HbA1c ) &gt; 8 % Visit 1 . Known suspected contraindication study medication , include history allergy ramipril ACE Inhibitors . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Hypertension , Aliskiren , Ramipril</keyword>
</DOC>